TPT-004

TPT-004 is a selective and oraly active tryptophan hydroxylases (TPH) inhibitor with IC50s of 77 nM and 16 nM for TPH1 and TPH2, repsectively. TPT-004 exhibits exceptional selectivity for TPH1 compared with other members of the AAAH family. TPT-004 shows efficacy peripheral serotonin attenuation and colorectal tumor growth in mice[1][2].

Product Specifications

CAS Number

[3032648-15-7]

UNSPSC

12352005

Target

Tryptophan Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tpt-004.html

Purity

99.90

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CCN1C2=C(C(NC1=O)=O)N(C(CC3=CN4C=C(SC4=N3)C)=N2)CC5COC5

Molecular Formula

C18H20N6O3S

Molecular Weight

400.45

References & Citations

[1]Specker E, et al. Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors. J Med Chem. 2023 Oct 31.|[2]Wesolowski R, et al. Selectivity and Safety Characterization of a Xanthine-Imidazothiazole Lead Structure: a Novel Tryptophan Hydroxylase Inhibitor of Peripheral Serotonin Synthesis. ACS Pharmacol Transl Sci. 2025 May 19;8 (6) :1678-1693.